(Q36916096)

17 August 2017

1 reference

title

Tipranavir: a new option for the treatment of drug-resistant HIV infection (English)

1 reference

17 August 2017

Zelalem Temesgen

1

1 reference

PubMed ID

17712762

17 August 2017

Judith Feinberg

series ordinal

2

1 reference

PubMed ID

17712762

17 August 2017

language of work or name

English

0 references

publication date

7 August 2007

1 reference

Clinical Infectious Diseases

17 August 2017

1 reference

17 August 2017

45

1 reference

17 August 2017

6

1 reference

17 August 2017

761-769

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

17 August 2017

1 reference

Decline in deaths from AIDS due to new antiretrovirals

21 January 2018

1 reference

HIV infection and vaginal douching in central Africa

21 January 2018

1 reference

Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients

21 January 2018

1 reference

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

21 January 2018

1 reference

Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors

21 January 2018

1 reference

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

21 January 2018

1 reference

How flexible is tipranavir in complex with the HIV-1 protease active site?

21 January 2018

1 reference

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

21 January 2018

1 reference

A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients

21 January 2018

1 reference

Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers

21 January 2018

1 reference

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

21 January 2018

1 reference

Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells

21 January 2018

1 reference

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir

21 January 2018

1 reference

Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/520847

1 reference

17 August 2017

1 reference

PubMed ID

17712762